• about us
• allosteric modulation
• pipeline
  • discovery pipeline
• key indications
• business development
• investor center
• press releases
• careers
• contact

ADX63365

ADX63365 is an mGluR5 PAM in late preclinical development, which is licensed to Merck & Co., Inc. Addex and Merck believe this mGluR5 PAM could have potential for the treatment of schizophrenia as well as other undisclosed indications involving cognitive impairment.


Back to pipeline